CalciMedica to Present at H.C. Wainwright 27th Global Investment Conference 2025

CalciMedica Prepares for Global Investment Conference

CalciMedica Inc. is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8, 2025. The company, which operates in the clinical-stage biopharmaceutical sector, focuses on developing innovative therapies that inhibit calcium release-activated calcium (CRAC) channels aimed at treating acute and chronic inflammatory and immunologic illnesses. The CEO, Dr. Rachel Leheny, will lead the presentation, bringing attention to the advancements CalciMedica has made in its therapeutic offerings.

Overview of CalciMedica

Founded with a vision to change the landscape of treatment for inflammatory and immunologic diseases, CalciMedica specializes in harnessing the potential of CRAC channel modulation. This technology is pivotal in managing immune responses and shielding tissue cells from injury, potentially addressing conditions that currently lack approved therapeutic interventions. CalciMedica's flagship product, Auxora™, has shown promise through consistent positive results across various clinical trials, demonstrating its safety profile in over 350 critically ill patients.

Focus on Clinical Trials and Research

CalciMedica's ongoing research efforts highlight the company's commitment to advancing medical treatment options. The company has released promising data from its Phase 2b trial (known as CARPO – NCT04681066) which investigates the use of Auxora™ in patients grappling with acute pancreatitis coupled with systemic inflammatory response syndrome (SIRS). Furthermore, insights from another trial (CARDEA – NCT04345614) directed at patients with COVID pneumonia have showcased the drug's potential.

Currently, the company is conducting a pivotal Phase 2 trial (KOURAGE – NCT06374797) targeting individuals suffering from acute kidney injury (AKI) associated with respiratory failure. These clinical studies are crucial as they pave the way toward securing further clinical validation and potential regulatory approvals needed to bring Auxora™ to market.

Upcoming Conference Presentation

During the conference, CalciMedica plans to outline its corporate strategy, clinical advancements, and future goals in the development of therapeutics for conditions where options are limited. Participants will have the opportunity to engage in a live webcast of the presentation, streamable via the